Does Radiation Therapy Improve Survival for Women with Ductal Carcinoma in Situ (DCIS)? Yes...and...No.
Set of risk factors predict which patients with ductal carcinoma in situ (DCIS) will see a survival benefit from radiation therapy after breast cancer surgery. (Source: BWH News)
Source: BWH News - February 1, 2016 Category: Hospital Management Source Type: news

Trends in Treatment Patterns and Outcomes for DCISTrends in Treatment Patterns and Outcomes for DCIS
Research finds that locoregional treatment of DCIS has changed dramatically over the last 20 years. Has your practice changed with the times? Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 22, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

USPSTF Breast Cancer Screening Recommendations Could Endanger Women
Washington, DC – If followed, new U.S. Preventive Services Task Force (USPSTF) breast cancer screening recommendations will result in thousands of unnecessary deaths each year and thousands more women enduring extensive and expensive treatment than if their cancer had been found early by an annual mammogram. To ensure access to mammography, Congress delayed for two years any changes to insurance coverage based on these recommendations, while breast cancer experts vet the recommendations and the process by which they were created. Women ages 40-and-older, and their families, should continue to impress upon lawmakers a...
Source: American College of Radiology - January 11, 2016 Category: Radiology Source Type: news

New USPSTF mammography guidelines serve up more of the same
They say a leopard can't change its spots, a saying that fits the U.S. Preventive...Read more on AuntMinnie.comRelated Reading: ACS: Breast cancer screening should begin at age 45 Mammography screening at 40 works, Lancet study finds USPSTF mammo recs would cut coverage for 17M women Group offers details on USPSTF breast screening meta-analysis USPSTF rejects expanded breast screening guidelinesComments: 1/12/2016 4:31:32 PMJohn Keen, MD Dr. Monticciolo: Actually, screening less will make "cancers" go away-the overdiagnosed ones. 35% of screen-detected cancers are DCIS in younger women, see the tables in A...
Source: AuntMinnie.com Headlines - January 11, 2016 Category: Radiology Source Type: news

DCIS Detection Tied to Reduced Invasive Cancer RiskDCIS Detection Tied to Reduced Invasive Cancer Risk
Detection and treatment of ductal carcinoma in situ (DCIS) may reduce the risk of subsequent invasive disease between mammography screenings, new findings suggest. Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 22, 2015 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Drug Trials in DCIS Almost a Wash (CME/CE)
(MedPage Today) -- Patient preference in side effects likely to influence choice of Arimidex or Nolvadex (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 14, 2015 Category: Journals (General) Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 12, 2015 Category: Cancer & Oncology Source Type: news

AI vs Tamoxifen for DCIS? A Toss-up, Unless…AI vs Tamoxifen for DCIS? A Toss-up, Unless…
Both anastrozole and tamoxifen were effective at preventing recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ. Age, toxicities should drive choice, say investigators. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

For women taking 2 leading breast cancer drugs, symptoms tend to vary by patient’s age
UCLA Jonsson Comprehensive Cancer Center Dr. Patricia Ganz A study of two leading breast cancer drugs has determined that the breast cancer symptoms women experience while taking those drugs — and the severity of those symptoms — tend to vary based on the patients’ ages. The findings could be an important step toward personalized medicine for women with breast cancer, said Dr. Patricia Ganz, director of the UCLA Jonsson Comprehensive Cancer Center’s Prevention and Control Research program and the study’s first author. The study examined data for 1,193 postmenopausal women with a type of breast cancer called duct...
Source: UCLA Newsroom: Health Sciences - December 11, 2015 Category: Universities & Medical Training Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer’s Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: WebMD Health)
Source: WebMD Health - December 11, 2015 Category: Consumer Health News Source Type: news

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
(American Association for Cancer Research) Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects, according to results from the phase III IBIS-II DCIS clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

DCIS patients receiving anastrozole reported symptoms different from those receiving tamoxifen
(American Association for Cancer Research) Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in outcomes related to quality of life but some differences in outcomes related to symptoms in the two treatment groups, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

Drug provides another treatment option for an early form of breast cancer
(Queen Mary, University of London) The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

More Early Breast Cancers Detected on Screening, Fewer Invasive Cancers Later? (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Detection of ductal carcinoma in situ (DCIS) during mammographic screening is associated with lower risk for invasive breast cancer in the following 3 years, according to a retrospective study in the Lancet Oncology.Researchers examined data on over 5.2 million women … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 7, 2015 Category: Primary Care Source Type: news